For example, the current practice of matching non-small cell lung cancer patients carrying EGFR mutations to afatinib/osimertinib/erlotinib small molecule class of therapies, whereas those with wildtype alleles to be administered with conventional chemotherapies13, 14, 38. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.